The biotech industry's engineered cells could become an $8 trillion market by 2035, notes Phys.org. But how do you keep them from being stolen? Their article notes "an uptick in the theft and smuggling of high-value biological materials, including specially engineered cells." In Science Advances, a team of U.S. researchers present a new approach to genetically securing precious biological material. They created a genetic combination lock in which the locking or encryption process scrambled the DNA of a cell so that its important instructions were non-functional and couldn't be easily read or used. The unlocking, or decryption, process involves adding a series of chemicals in a precise order over time — like entering a password — to activate recombinases, which then unscramble the DNA to their original, functional form...

They created a biological keypad with nine distinct chemicals, each acting as a one-digit input. By using the same chemicals in pairs to form two-digit inputs, where two chemicals must be present simultaneously to activate a sensor, they expanded the keypad to 45 possible chemical inputs without introducing any new chemicals. They also added safety penalties — if someone tampers with the system, toxins are released — making it extremely unlikely for an unauthorized person to access the cells.
"The researchers conducted an ethical hacking exercise on the test lock and found that random guessing yielded a 0.2% success rate, remarkably close to the theoretical target of 0.1%."

"A surgeon in London says he has performed the UK's first long-distance robotic operation," reports the BBC, "on a patient located 1,500 miles (2,400km) away..." Leading robotic urological surgeon Professor Prokar Dasgupta said it felt "almost as if I was there" as he carried out a prostate removal on [62-year-old] Paul Buxton... It is hoped that remote robotic surgery could spare future patients the "vast expense and inconvenience" of travelling for treatment, and help deliver better healthcare to people in more remote locations... Buxton had expected to be put on an NHS waiting list after receiving a shock prostate cancer diagnosis just after Christmas, but he "jumped at the chance" to be the first patient to undergo the treatment remotely as part of a trial. "A lot of people actually said to me: 'You're not going to do it, are you?'

"I thought, I'm giving something back here," he said...

The operation was performed from The London Clinic using a robot equipped with a 3D HD camera and four arms, all controlled through a console with a delay of only 0.06 seconds. The console in the UK was connected to the robot in Gibraltar via fibre-optic cables, with a backup 5G link. A team in Gibraltar remained on standby in case the connection failed, but it held throughout the procedure...

Dasgupta will perform the procedure again on 14 March, which will be live-streamed to 20,000 world-leading urological surgeons at the European Association of Urology congress. He added: "I think it is very, very exciting, the humanitarian benefit is going to be significant."
The U.K.'s National Health Service "is prioritising local robotic-assisted surgery," the article points out, "aiming for 500,000 robot-supported operations a year by 2035."

Thanks to Slashdot reader fjo3 for sharing the article.

The Wall Street Journal reports that Boston's once-booming biotech sector has hit a sharp downturn, leaving newly minted Ph.D.s struggling to find work as venture funding dries up, lab space sits empty, and companies downsize or relocate amid rising costs and policy uncertainty. The Wall Street Journal reports: Boston's biotech sector, long a vital economic engine for one of America's wealthiest metro areas, is sputtering. A double whammy of cutbacks in venture capital and government funding have taken a toll, leading to layoffs and struggles for job seekers. For workers who thought they would easily launch into a well-paying science career, the downturn has been especially harsh.

Massachusetts experienced a slight decline in its roughly 65,000 biotech research-and-development jobs in 2024 after years of mostly strong increases, including during the Covid-19 pandemic, according to federal data. The numbers indicate that job losses continued through at least June, while hiring remains sluggish. By the end of September, nearly 28% of greater Boston's laboratory space sat empty, according to the latest estimates from real-estate firm CBRE. "Every stage of the life cycle has been impacted by policy or regulatory uncertainty this year," said Kendalle Burlin O'Connell, chief executive of MassBio, an industry trade group. The impact has hit startups especially hard, she said.

A continued downturn poses risks for a region where workers will put up with sky-high real-estate costs if they can land high-paying jobs. Massachusetts faces competition from other states and China, which are eager to peel away talent and investment. "There are states and countries chasing us every single day," Gov. Maura Healey said in an interview. In late October, the Democrat testified before the Massachusetts legislature in support of a $400 million "competitiveness agenda" that she is seeking to spur new investment and supplement research funding lost this year. Lawmakers are reviewing the bill, a House spokesman said.

An anonymous reader quotes a report from the New York Times: Since online genealogy services began operating, millions of people have sent them saliva samples in hopes of learning about their family roots and discovering far-flung relatives. These services also appeal to law enforcement authorities, who have used them to solve cold case murders and to investigate crimes like the 2022 killing of four University of Idaho students. Crime-scene DNA submitted to genealogy sites has helped investigators identify suspects and human remains by first identifying relatives.

The use of public records and family-tree building is crucial to this technique, and its main tool has been the genealogy site Ancestry, which has vast amounts of individual DNA profiles and public records. More than 1,400 cases have been solved with the help of so-called genetic genealogy investigations, most of them with help from Ancestry. But a recent step taken by the site is now deterring many police agencies from employing this crime-solving technique.

In August, Ancestry revised the terms and conditions on its site to make it clear that its services were off-limits "for law enforcement purposes" without a legal order or warrant, which can be hard to get, because of privacy concerns. This followed the addition last year to the terms and conditions that the services could not be used for "judicial proceedings." Investigators say the implications are dire and will result in crucial criminal cases slowing or stalling entirely, denying answers to grieving families. "Everyone who does this work has depended on the records database that Ancestry controls," said David Gurney, who runs Ramapo College's Investigative Genetic Genealogy Center in New Jersey. "Without it, casework is going to be a lot slower, and there will be some cases that can't be resolved at all."

Washington Post columnist Dana Milbank calls himself "a highly creative hypochondriac" — who just paid for an expensive MRI scan to locate abnormal spots as tiny as 2 millimeters.

He discusses the pros and cons of its "diffusion-weighted imaging" technology combined with the pattern recognition of AI, which theoretically "has the potential to save our lives by revealing budding cancers, silent aneurysms and other hidden would-be killers before they become deadly. " But the scans cost $2,500 a pop and insurance won't pay. Worse, for every cancer these MRIs find, they produce a slightly greater number of false positives that require a biopsy, with the potential for infection and bleeding and emotional distress. Even when the scans don't produce a false positive, they almost always come up with some vague and disconcerting abnormality.... Will we feel better after viewing our insides? Or will we become anxious about things we hadn't even thought to worry about?

Part of living has always been in the mystery, in not knowing what tomorrow will bring. Now, because of sophisticated imaging, genome sequencing and other revolutionary screening tools, we can have predictability, or at least the illusion of it. But do we want that? The American College of Radiology says we do not. Its still-current 2023 statement says there is not "sufficient evidence" to recommend full-body screening, cautioning that the scan could lead to needless testing and expense. But David Larson, chair of ACR's Commission on Quality and Safety, told me that could change as more data comes in. "When people ask me, 'Would you recommend it?' I would say it depends on your tolerance for ambiguity," he said, giving the example of somebody found to have a borderline aortic aneurysm who is advised to wait and monitor it. If "that won't keep you up at night, then I wouldn't necessarily recommend against it...."

About 1 in 20 gets that dreaded call. A study Prenuvo presented earlier this year of 1,011 participants found that 4.9 percent of scans required a follow-up biopsy. Of those, 2.2 percent were actually cancer, and the other 2.7 percent were false positives. Of the 22 cancers the scans caught, 86 percent of patients had no specific symptoms. But if finding something truly awful is rare, finding something abnormal is almost guaranteed. [Vikash Modi, Prenuvo's senior medical director of preventative medicine] said only 1 in 20 scans come back completely clean. The vast majority of patients wind up in the ambiguous realm where something may look suspicious but doesn't require urgent follow-up.
He opted for the cheaper $1,000 torso scan, which the senior medical director calls "our bread-and-butter area," since 17 of the 22 cancers detected in one Prenuvo study were in that area and is where they often find cancers that wouldn't be discovered until they were incurable like "that scary pancreatic stuff...."

Milbank's scan found 12 "abnormalities" included "a 2.5 mm pulmonary nodule in the right lower lobe" and "a 4.6 mm intraductal papillary mucinous neoplasm in the pancreatic tail" — but with 10 abnormalities labeled "minor" (and six being musculoskeletal wear-and-tear problems "I already knew about from the usual aches and pains".) Even the two "moderate" findings didn't sound that grim when I read on. The "indeterminant lesion" in my lung requires no follow-up, while the thing in my pancreas is "low-risk."... The "most interesting" finding was the pancreatic cyst, because, at this size and location, there's a 3 percent chance it will become cancerous in the next five years. But if annual follow-up scans of my pancreas (covered by insurance) show it's getting bigger, the cyst can be removed before it becomes cancer. For me, this made the MRI worthwhile. Sure, there was a 97 percent likelihood the cyst never would develop into a problem even if I hadn't learned about it. But now, with minimal inconvenience, I can eliminate that 3 percent risk of getting pancreatic cancer, the most lethal of major malignancies.

BrianFagioli writes: President Trump has issued a sweeping executive order that creates the Genesis Mission, a national AI program he compares to a Manhattan Project level effort. It centralizes DOE supercomputers, national lab resources, massive scientific datasets, and new AI foundation models into a single platform meant to fast track research in areas like fusion, biotech, microelectronics, and advanced manufacturing. The order positions AI as both a scientific accelerator and a national security requirement, with heavy emphasis on data access, secure cloud environments, classification controls, and export restrictions.

The mission also sets strict timelines for identifying key national science challenges, integrating interagency datasets, enabling AI run experimentation, and creating public private research partnerships. Whether this becomes an effective scientific engine or another oversized federal program remains to be seen, but the administration is clearly pushing to frame Trump as the president who put AI at the center of U.S. research strategy.

The Washington Post reports: Scientists in Switzerland have created a robot the size of a grain of sand that is controlled by magnets and can deliver drugs to a precise location in the human body, a breakthrough aimed at reducing the severe side effects that stop many medicines from advancing in clinical trials... "I think surgeons are going to look at this," [said Bradley J. Nelson, an author of the paper in Science describing the discovery and a professor of robotics and intelligent systems at ETH Zurich]. I'm sure they're going to have a lot of ideas on how to use" the microrobot. The capsule, which is steered by magnets, might also be useful in treating aneurysms, very aggressive brain cancers, and abnormal connections between arteries and veins known as arteriovenous malformations, Nelson said. The capsules have been tested successfully in pigs, which have similar vasculature to humans, and in silicone models of the blood vessels in humans and animals... Nelson said drug-ferrying microrobots of this kind may be three to five years from being tested in clinical trials. The problem faced by many drugs under development is that they spread throughout the body instead of going only to the area in need... A major cause of side effects in patients is medications traveling to parts of the body that don't need them. The capsules developed in Switzerland, however, can be maneuvered into precise locations by a surgeon using a tool not that different from a PlayStation controller. The navigation system involves six electromagnetic coils positioned around the patient, each about 8 to 10 inches in diameter... The capsules are made of materials that have been found safe for people in other medical tools...

When the capsule reaches its destination in the body, "we can trigger the capsule to dissolve," Nelson said.

A Chinese man who cryogenically preserved his wife after her death has sparked a heated online debate after it emerged he began dating a new partner in 2020. Some argue it's natural for him to move on, while others say he's being selfish or disrespectful to both his late wife and his current partner. The BBC reports: As a sign of his devotion, Gui Junmin decided to freeze his wife Zhan Wenlian's body after she died from lung cancer in 2017, aged 49, making her China's first cryogenically preserved person. But after a November interview revealed he had been dating a different partner since 2020, Chinese social media has been torn on Mr Junmin's predicament. Whilst some asked why the 57-year-old didn't just "let go" another commenter remarked he appeared to be "most devoted to himself."

After Zhan Wenlian was given months to live by doctors, Gui Junmin decided to use cryonics - which is scientifically unproven - to preserve her body once she died. Following her death, he signed a 30-year agreement to preserve his wife's frozen body with the Shandong Yinfeng Life Science Research Institute. Since then, Zhan's body has been stored in a 2,000-litre container at the institute in a vat of -190C liquid nitrogen.

Chinese newspaper Southern Weekly revealed that although Mr Junmin lived alone for two years after the procedure, in 2020 he began dating again, despite his wife remaining in cryopreservation. He told the newspaper that a severe gout attack which left him unable to move for two days began to change his mind about the benefits of living alone. Soon after, he started seeing his current partner Wang Chunxia, although Mr Junmin suggested to the paper the love was only "utilitarian" and that she hadn't "entered" his heart.

An anonymous reader shares a report: Executives are turning to a novel structure to fund crypto accumulation vehicles as investor appetite thins. They're called in-kind contributions, and they now account for a growing share of digital-asset treasury, or DAT, deals. Instead of raising cash to buy tokens in the open market, DAT sponsors contribute large slugs of their own crypto, often unlisted and hard to value.

Digital-asset treasuries are a new breed of public company built to hold concentrated crypto positions. The structure surged in 2025 as small-cap firms, especially in biotech and mining, reinvented themselves as digital-asset proxies. Sponsors provide tokens or raise money to buy them, and the stock then trades as a kind of listed bet on crypto. For insiders, it's a shortcut to liquidity. For investors, a wager on upside. But not all DATs carry the same level of risk. Earlier deals raised money to buy tokens through regular markets, which offered at least some independent price check. In-kind contributions skip that step -- letting insiders decide what their tokens are worth, sometimes before the token even trades publicly. That shift means pricing and trading risks land more squarely on shareholders, many of them retail investors.

Investor faith is already wobbling. Many DATs that once traded above the value of their holdings now trade below it. As insiders supply the tokens and set their price, it's becoming harder for investors to tell what these deals are really worth, or when to get out. The in-kind structure was on full display in a recent $545 million private placement by Tharimmune Inc., a biotech firm-turned-crypto proxy, to set up a buyer of Canton Coins. About 80% of the raise came in the form of unlisted Canton tokens, priced at 20 cents each, according to an investor presentation seen by Bloomberg News. The token began trading on exchanges Nov. 10 and is now around 11 cents, CoinGecko data show.

More deals are following the same template. In these placements, insiders contribute tokens -- sometimes illiquid or unlisted -- to form a treasury, lock in valuations and seed the perception of market demand. But when tokens list below deal price, public shareholders absorb the difference. [...] Then there's Flora Growth Corp., a Nasdaq-listed company that announced a $401 million deal to start acquiring Zero Gravity tokens in September. On closer inspection, the firm had raised just $35 million in cash to pair with a $366 million in-kind contribution of then-unlisted 0G tokens. Those tokens were priced at around $3 a piece; they subsequently listed, and are now trading at about $1.20.

"For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby," reports the Wall Street Journal: Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup — called Preventive — has been quietly preparing what would amount to a biological first. They are working toward creating a child born from an embryo edited to prevent a hereditary disease.... Editing genes in embryos with the intention of creating babies from them is banned in the U.S. and many countries. Preventive has been searching for places to experiment where embryo editing is allowed, including the United Arab Emirates, according to correspondence reviewed by The Wall Street Journal...

Preventive is in the vanguard of a growing number of startups, funded by some of the most powerful people in Silicon Valley, that are pushing the boundaries of fertility and working to commercialize reproductive genetic technologies. Some are working on embryo editing, while others are already selling genetic screening tools that seek to account for the influence of dozens or hundreds of genes on a trait. They say their ultimate goal is to produce babies who are free of genetic disease and resilient against illnesses. Some say they can also give parents the ability to choose embryos that will have higher IQs and preferred traits such as height and eye color. Armstrong, the cryptocurrency billionaire, is leading the charge to make embryo editing a reality. He has told people that gene-editing technology could produce children who are less prone to heart disease, with lower cholesterol and stronger bones to prevent osteoporosis. According to documents and people briefed on his plans, he is already an investor or in talks with embryo editing ventures...

After the Journal approached people close to the company last month to ask about its work, Preventive announced on its website that it had raised $30 million in investment to explore embryo editing. The statement pledged not to advance to human trials "if safety cannot be established through extensive research..." Other embryo editing startups are Manhattan Genomics, co-founded by Thiel Fellow Cathy Tie, and Bootstrap Bio, which plans to conduct tests in Honduras. Both companies are in early stages.
The article notes the only known instance of children born from edited embryos was in 2018, when Chinese scientist He Jiankui "shocked the world with news that he had produced three children genetically altered as embryos to be immune to HIV. He was sentenced to prison in China for three years for the illegal practice of medicine.

"He hasn't publicly shared the children's identities but says they are healthy.

A CRISPR-based drug given to study participants by infusion is raising hopes for a much easier way to lower cholesterol, reports CNN: With a snip of a gene, doctors may one day permanently lower dangerously high cholesterol, possibly removing the need for medication, according to a new pilot study published Saturday in the New England Journal of Medicine.

The study was extremely small — only 15 patients with severe disease — and was meant to test the safety of a new medication delivered by CRISPR-Cas9, a biological sort of scissor which cuts a targeted gene to modify or turn it on or off. Preliminary results, however, showed nearly a 50% reduction in low-density lipoprotein, or LDL, the "bad" cholesterol which plays a major role in heart disease — the No.1 killer of adults in the United States and worldwide. The study, which will be presented Saturday at the American Heart Association Scientific Sessions in New Orleans, also found an average 55% reduction in triglycerides, a different type of fat in the blood that is also linked to an increased risk of cardiovascular disease.

"We hope this is a permanent solution, where younger people with severe disease can undergo a 'one and done' gene therapy and have reduced LDL and triglycerides for the rest of their lives," said senior study author Dr. Steven Nissen, chief academic officer of the Sydell and Arnold Miller Family Heart, Vascular & Thoracic Institute at Cleveland Clinic in Ohio.... Today, cardiologists want people with existing heart disease or those born with a predisposition for hard-to-control cholesterol to lower their LDL well below 100, which is the average in the US, said Dr. Pradeep Natarajan, director of preventive cardiology at Massachusetts General Hospital and associate professor of medicine at Harvard Medical School in Boston...

People with a nonfunctioning ANGPTL3 gene — which Natarajan says applies to about 1 in 250 people in the US — have lifelong levels of low LDL cholesterol and triglycerides without any apparent negative consequences. They also have exceedingly low or no risk for cardiovascular disease. "It's a naturally occurring mutation that's protective against cardiovascular disease," said Nissen, who holds the Lewis and Patricia Dickey Chair in Cardiovascular Medicine at Cleveland Clinic. "And now that CRISPR is here, we have the ability to change other people's genes so they too can have this protection."
"Phase 2 clinical trials will begin soon, quickly followed by Phase 3 trials, which are designed to show the effect of the drug on a larger population, Nissen said."

And CNN quotes Nissen as saying "We hope to do all this by the end of next year. We're moving very fast because this is a huge unmet medical need — millions of people have these disorders and many of them are not on treatment or have stopped treatment for whatever reason."

The Associated Press reports that "For the past decade, Dr. Priscilla Chan and her husband Mark Zuckerberg have focused part of their philanthropy on a lofty goal — 'to cure, prevent or manage all disease' — if not in their lifetime, then in their children's."

During that decade they also funded other initiatives (including underprivileged schools and immigration reform), according to the article. But there's a change coming: Now, the billionaire couple is shifting the bulk of their philanthropic resources to Biohub, the pair's science organization, and focusing on using artificial intelligence to accelerate scientific discovery. The idea is to develop virtual, AI-based cell models to understand how they work in the human body, study inflammation and use AI to "harness the immune system" for disease detection, prevention and treatment. "I feel like the science work that we've done, the Biohub model in particular, has been the most impactful thing that we have done. So we want to really double down on that. Biohub is going to be the main focus of our philanthropy going forward," Zuckerberg said Wednesday evening at an event at the Biohub Imaging Institute in Redwood City, California.... Chan and Zuckerberg have pledged 99% of their lifetime wealth — from shares of Meta Platforms, where Zuckerberg is CEO — toward these efforts...

On Thursday, Chan and Zuckerberg also announced that Biohub has hired the team at EvolutionaryScale, an AI research lab that has created large-scale AI systems for the life sciences... Biohub's ambition for the next years and decades is to create virtual cell systems that would not have been possible without recent advances in AI. Similar to how large language models learn from vast databases of digital books, online writings and other media, its researchers and scientists are working toward building virtual systems that serve as digital representations of human physiology on all levels, such as molecular, cellular or genome. As it is open source — free and publicly available — scientists can then conduct virtual experiments on a scale not possible in physical laboratories.
"We will continue the model we've pioneered of bringing together scientists and engineers in our own state-of-the-art labs to build tools that advance the field," according to Thursday's blog post. "We'll then use those tools to generate new data sets for training new biological AI models to create virtual cells and immune systems and engineer our cells to detect and treat disease....

"We have also established the first large-scale GPU cluster for biological research, as well as the largest datasets around human cell types. This collection of resources does not exist anywhere else."

China is accelerating its biotech ambitions by pushing the limits of animal testing and gene editing (source paywalled; alternative source) while Western countries tighten ethical restrictions. "Editing the genes of large animals such as pigs, monkeys and dogs faces scant regulation in China," reports Bloomberg. "Meanwhile, regulators in the US and Europe demand layers of ethical reviews, rendering similar research involving large animals almost impossible." From the report: Backing the work of China's scientists is not only permissiveness but state money. In 2023 alone, the Chinese government funneled an estimated $3 billion into biotech. Its sales of cell and gene therapies are projected to reach $2 billion by 2033 from $300 million last year. On the Chinese researchers' side are government-supported breeding and research centers for gene-edited animals and a public largely in approval of pushing the boundaries of animal testing.

The country should become "a global scientific and technology power," Xi said, declaring biotechnology and gene editing a strategic priority. For decades, the country's pharmaceutical companies specialized in generics, reproducing drugs already pioneered elsewhere. Delving head first into gene editing research may be key to China's plan to develop innovative drugs as well as reduce its dependence on foreign pharmaceutical companies.

The result is a country that now dominates headlines with stories of large, genetically modified animals being produced for science -- and the catalog is startling. Its scientists have created monkeys with schizophrenia, autism and sleep disorders. They were the first to clone primates. They've engineered dogs with metabolic and neurological diseases, and even cloned a gene-edited beagle with a blood-clotting disorder.

AstraZeneca has licensed Algen Biotechnologies' AI-powered gene-editing platform, AlgenBrain, to develop immune-related therapies in a deal worth up to $555 million. Reuters reports: AstraZeneca will get exclusive rights to develop and sell approved therapies, if any, that target immune system-related disorders in exchange for upfront and milestone payments to Algen. AstraZeneca has been advancing its cell and gene therapy capabilities through acquisitions and partnerships as it works towards its target of $80 billion in sales by 2030. Globally too, drugmakers are increasingly turning to artificial intelligence for drug development.

Monday's deal, however, does not include AstraZeneca buying a stake in the company, Algen CEO and co-founder Chun-Hao Huang told Reuters in an interview. "Together with AstraZeneca's deep expertise in translational science and clinical development, we aim to uncover new biological insights to accelerate the development of novel therapies," Huang said. Algen was spun out from the UC Berkeley lab where biochemist Jennifer Doudna pioneered the CRISPR technology that won her the Nobel Prize. The biotech firm's AI platform, AlgenBrain, can map genes to disease outcomes, helping the companies decide their development focus for targeted therapies.

California biotech entrepreneur and former magician Serhat Gumrukcu has been found guilty of orchestrating the 2018 murder of his business rival Gregory Davis, who had threatened to expose Gumrukcu's fraudulent dealings. He faces sentencing in November. SFGATE reports: Seven years ago, Turkish national Serhat Gumrukcu, 42, of Los Angeles, was negotiating a multimillion-dollar biotech merger built off his work on a supposed HIV cure. The deal was put in jeopardy by a former business partner named Gregory Davis, 49, who had threatened to bring legal action against Gumrukcu for fraudulent activities relating to a previous failed oil commodities deal, the U.S. Attorney's Office said in a news release last week. Gumrukcu, a magician-turned-scientist who admitted to buying his medical degree from a Russian university, lived in a Hollywood mansion and partied with Oscar winners and movie producers, according to VTDigger. He stood to make millions from the merger of his biotech company Enochian BioSciences. [...]

In 2017, upon learning that Davis, a father of six from Danville, Vermont, could potentially spoil his fortune-making deal, Gumrukcu set in motion a hit on the former business partner. The murder-for-hire plot involved four men in total, prosecutors said. Gumrukcu had a close friend from Las Vegas, Berk Eratay, approach a third man, Aron Ethridge to find a hit man to kill Davis. The shooter, 37-year-old Montana man Jerry Banks, arrived at Davis' home on Jan. 6, 2018, in a vehicle fitted with flashing red and blue lights and posed as a deputy U.S. marshal. After abducting Davis, Banks shot him dead in the vehicle and left the body partially buried in a snowbank nearby.

Investigators soon narrowed in on Gumrukcu after discovering emails between him and Davis revealing tensions over the failed oil deal. Gumrukcu was interviewed twice by the FBI and made false statements on both occasions, federal prosecutors said. Further inspection of cellphone data, bank information and messages identified the four men involved in the kidnapping and killing of Davis.

An anonymous reader quotes a report from MIT Technology Review: A team at Microsoft says it used artificial intelligence to discover a "zero day" vulnerability in the biosecurity systems used to prevent the misuse of DNA. These screening systems are designed to stop people from purchasing genetic sequences that could be used to create deadly toxins or pathogens. But now researchers led by Microsoft's chief scientist, Eric Horvitz, says they have figured out how to bypass the protections in a way previously unknown to defenders.The team described its work today in the journalScience.

Horvitz and his team focused on generative AI algorithms that propose new protein shapes. These types of programs are already fueling the hunt for new drugs at well-funded startups like Generate Biomedicines and Isomorphic Labs, a spinout of Google. The problem is that such systems are potentially "dual use." They can use their training sets to generate both beneficial molecules and harmful ones. Microsoft says it began a "red-teaming" test of AI's dual-use potential in 2023 in order to determine whether "adversarial AI protein design" could help bioterrorists manufacture harmful proteins.

The safeguard that Microsoft attacked is what's known as biosecurity screening software. To manufacture a protein, researchers typically need to order a corresponding DNA sequence from a commercial vendor, which they can then install in a cell. Those vendors use screening software to compare incoming orders with known toxins or pathogens. A close match will set off an alert. To design its attack, Microsoft used several generative protein models (including its own, called EvoDiff) to redesign toxins -- changing their structure in a way that let them slip past screening software but was predicted to keep their deadly function intact. "This finding, combined with rapid advances in AI-enabled biological modeling, demonstrates the clear and urgent need for enhanced nucleic acid synthesis screening procedures coupled with a reliable enforcement and verification mechanism," says Dean Ball, a fellow at the Foundation for American Innovation, a think tank in San Francisco.

"Researchers have modified a standard glue gun to 3D print a bone-like material directly onto fractures," reports LiveScience, "paving the way for its use in operating rooms." The device, which has so far been tested in rabbits, would be particularly useful for fixing irregularly shaped fractures during surgery, the researchers say.

"To my knowledge, there are virtually no previous examples of applying the technology directly as a bone substitute," study co-author Jung Seung Lee, a biomedical engineer at Sungkyunkwan University in South Korea, told Live Science in an email. "This makes the approach quite unique and sets it apart from conventional methods...." "Further studies in larger animal models are needed before the technology can be used on humans," the article points out.

Thanks to long-time Slashdot reader fahrbot-bot for sharing the article.

Many Apple Watches will soon be able to alert users about possible high blood pressure, reports Reuters — culminating six years of research and development: Apple used AI to sort through the data from 100,000 people enrolled in a heart and movement study it originally launched in 2019 to see whether it could find features in the signal data from the watch's main heart-related sensor that it could then match up with traditional blood pressure measurements, said Sumbul Ahmad Desai [Apple's vice president of health]. After multiple layers of machine learning, Apple came up with an algorithm that it then validated with a specific study of 2,000 participants.

Apple's privacy measures mean that "one of the ironies here is we don't get a lot of data" outside of the context of large-scale studies, Desai said. But data from those studies "gives us a sense of, scientifically, what are some other signals that are worth pulling the thread on ... those studies are incredibly powerful."

The feature, which received approval from the U.S. Food and Drug Administration, does not measure blood pressure directly, but notifies users that they may have high blood pressure and encourages them to use a cuff to measure it and talk to a doctor. Apple plans to roll out the feature to more than 150 countries, which Ami Bhatt, chief innovation officer of the American College of Cardiology, said could help people discover high blood pressure early and reduce related conditions such as heart attacks, strokes and kidney disease. Bhatt, who said her views are her own and do not represent those of the college, said Apple appears to have been careful to avoid false positives that might alarm users. But she said the iPhone maker should emphasize that the new feature is no substitute for traditional measurements and professional diagnosis.
The article notes that the feature will be available in Apple Watch Series 11 models that go on sale on Friday, as well as models back to the Apple Watch Series 9.

A U.S.-China research team has developed the world's first one-step process to convert mixed plastic waste into gasoline and hydrochloric acid with up to 95-99% efficiency, all at room temperature and ambient pressure. InterestingEngineering reports: As the authors put it, "The method supports a circular economy by converting diverse plastic waste into valuable products in a single step." To carry out the conversion, the team combines plastic waste with light isoalkanes, hydrocarbon byproducts available from refinery processes. According to the paper, the process yields "gasoline range" hydrocarbons, mainly molecules with six to 12 carbons, which are the primary component of gasoline. The recovered hydrochloric acid can be safely neutralized and reused as a raw material, potentially displacing several high-temperature, energy-intensive production routes described in the paper. "We present here a strategy for upgrading discarded PVC into chlorine-free fuel range hydrocarbons and [hydrochloric acid] in a single-stage process," the researchers said. Reported conversion efficiencies underscore the potential for real-world use. At 86 degrees Fahrenheit (30 degrees Celsius), the process reached 95 percent conversion for soft PVC pipes and 99 percent for rigid PVC pipes and PVC wires.

In tests that mixed PVC materials with polyolefin waste, the method achieved a 96 percent solid conversion efficiency at 80 degrees Celsius (176 degrees Fahrenheit). The team describes the approach as applicable beyond laboratory-clean samples. "The process is suitable for handling real-world mixed and contaminated PVC and polyolefin waste streams," the paper states. SCMP points to an ECNU social media post citing the study, which characterized the achievement as a first, efficiently converting difficult-to-degrade mixed plastic waste into premium petrol at ambient temperature and pressure in a single step.

Struggling small biotech firms are pivoting into cryptocurrencies, rebranding as "crypto treasuries" or stockpiling digital assets like Ether and Litecoin as a last-ditch effort to boost share prices amid stalled funding and weak drug pipelines. Bloomberg reports: Shares of 180 Life Sciences Corp., now doing business as ETHZilla, tripled after the Peter Thiel-backed company said it had accumulated Ether tokens worth over $350 million. Less than two weeks later, the stock's gains have been erased. In July, Sonnet BioTherapeutics Holdings soared 243% in one volatile session on plans to transform into a public crypto treasury while MEI Pharma Inc. initially doubled on plans to sell shares to fund a Litecoin treasury.

Such about-faces are a tried-and-true formula for small firms when funds are low and shares are under pressure. For drugmakers it can be a sudden shift to chase after trendy new treatment targets, still other companies rebrand with buzzwords like artificial intelligence to juice returns. Now some biotech executives are using digital coins to pump new life into flagging shares. So far in 2025, at least 10 biotechs have announced a pivot into digital assets. The announcements frequently spark frenzied, but short-lived, spikes in shares. "If they're low on ideas, if they can't find relevance in drug development, they're going to try to justify their existence as management in another way," according to Mike Taylor, lead portfolio manager of the Simplify Health Care ETF. "You have a handful of companies trying to reinvent themselves into some other tangent. And, most, if not all won't work out."